Pharmacokinetics, pharmacodynamics, and safety of HE009, a novel selective S1P1 receptor modulator, in healthy Chinese subjects
The trial was registered on the Chinese Clinical Trial Registry, (Identifier No. ChiCTR2200066345), Registered December 1, 2022.
Authors
- Yuanhao Zuo (ORCID: https://orcid.org/0009-0002-9475-3937)
- Qin Yang (ORCID: https://orcid.org/0000-0003-3566-8898)
- Liang Zheng
- Wei Hu (ORCID: https://orcid.org/0000-0002-4809-7601)
- Shaoang Tu (ORCID: https://orcid.org/0000-0002-9765-0952)
- Qian Zhang (ORCID: https://orcid.org/0000-0002-2959-0863)
- Qin Zhang (ORCID: https://orcid.org/0009-0009-5451-4051)
- Tao Lin (ORCID: https://orcid.org/0000-0003-1170-636X)
- Jie Ding
- Peng Deng
- Zhiwei Yao
Institutions
- Anhui Medical University (CN)
- Buchang Pharma (China) (CN)
- Anhui Provincial Hospital (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
Publication Details
- Journal
- Expert Opinion on Investigational Drugs
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1080/13543784.2025.2570244
- Primary Topic
- Sphingolipid Metabolism and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00